Also from this source

You just read:

Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease

News provided by

Intercept Pharmaceuticals, Inc.

Mar 30, 2011, 06:03 ET